Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC).ESCC is a type of cancer that starts in certain cells that line the esophagus. Theesophagus is the tube that connects the throat to the stomach. This study will look atESCC that is either locally advanced unresectable, which means it has spread into tissuenear where it started and cannot be completely removed by surgery, or metastatic, whichmeans it has spread to other body parts.Available treatments for these types of ESCC include pembrolizumab and chemotherapy.Pembrolizumab is an immunotherapy, which is a treatment that helps the immune systemfight cancer. Chemotherapy is medicine that destroys cancer cells or stops them fromgrowing.Researchers want to learn about giving pembrolizumab and ifinatamab deruxtecan (I-DXd), astudy medicine, with or without chemotherapy to treat ESCC. I-DXd is an antibody-drugconjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment todestroy
Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC).ESCC is a type of cancer that starts in certain cells that line the esophagus. Theesophagus is the tube that connects the throat to the stomach. This study will look atESCC that is either locally advanced unresectable, which means it has spread into tissuenear where it started and cannot be completely removed by surgery, or metastatic, whichmeans it has spread to other body parts.Available treatments for these types of ESCC include pembrolizumab and chemotherapy.Pembrolizumab is an immunotherapy, which is a treatment that helps the immune systemfight cancer. Chemotherapy is medicine that destroys cancer cells or stops them fromgrowing.Researchers want to learn about giving pembrolizumab and ifinatamab deruxtecan (I-DXd), astudy medicine, with or without chemotherapy to treat ESCC. I-DXd is an antibody-drugconjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment todestroy
